Outlook Therapeutics Provides Business Update and Reports Financial Results for the First Quarter of Fiscal Year 2020

NEXT STORY
RECORDATI: I RISULTATI PRELIMINARI 2019 CONFERMANO LA CONTINUA CRESCITA DEI RICAVI E DEGLI UTILI. RICAVI +9,6%, EBITDA +9,0%
PREV STORY
Helix BioPharma Corp. to Present at the Noble Capital Markets’ Sixteenth Annual Investor Conference
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Novartis and Molecular Partners report positive topline data from Phase 2 study for ensovibep (MP0420), a DARPin antiviral therapeutic for COVID-19

author_avatar
NASDAQ Market News

Ad hoc: Valneva Announces Termination of 2013 Shareholder Agreement

author_avatar
NASDAQ Market News

Roche receives FDA approval for first companion diagnostic to identify endometrial cancer patients eligible for immunotherapy

author_avatar
NASDAQ Market News